361 related articles for article (PubMed ID: 34022071)
1. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria.
Forbes TA; Brown BD; Lai C
Br J Clin Pharmacol; 2022 Jun; 88(6):2525-2538. PubMed ID: 34022071
[TBL] [Abstract][Full Text] [Related]
2. Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria.
Lai C; Pursell N; Gierut J; Saxena U; Zhou W; Dills M; Diwanji R; Dutta C; Koser M; Nazef N; Storr R; Kim B; Martin-Higueras C; Salido E; Wang W; Abrams M; Dudek H; Brown BD
Mol Ther; 2018 Aug; 26(8):1983-1995. PubMed ID: 29914758
[TBL] [Abstract][Full Text] [Related]
3. Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.
Frishberg Y; Deschênes G; Groothoff JW; Hulton SA; Magen D; Harambat J; Van't Hoff WG; Lorch U; Milliner DS; Lieske JC; Haslett P; Garg PP; Vaishnaw AK; Talamudupula S; Lu J; Habtemariam BA; Erbe DV; McGregor TL; Cochat P;
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1025-1036. PubMed ID: 33985991
[TBL] [Abstract][Full Text] [Related]
4. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
Garrelfs SF; Frishberg Y; Hulton SA; Koren MJ; O'Riordan WD; Cochat P; Deschênes G; Shasha-Lavsky H; Saland JM; Van't Hoff WG; Fuster DG; Magen D; Moochhala SH; Schalk G; Simkova E; Groothoff JW; Sas DJ; Meliambro KA; Lu J; Sweetser MT; Garg PP; Vaishnaw AK; Gansner JM; McGregor TL; Lieske JC;
N Engl J Med; 2021 Apr; 384(13):1216-1226. PubMed ID: 33789010
[TBL] [Abstract][Full Text] [Related]
5. New therapeutics for primary hyperoxaluria type 1.
Dejban P; Lieske JC
Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):344-350. PubMed ID: 35266883
[TBL] [Abstract][Full Text] [Related]
6. Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
Michael M; Groothoff JW; Shasha-Lavsky H; Lieske JC; Frishberg Y; Simkova E; Sellier-Leclerc AL; Devresse A; Guebre-Egziabher F; Bakkaloglu SA; Mourani C; Saqan R; Singer R; Willey R; Habtemariam B; Gansner JM; Bhan I; McGregor T; Magen D
Am J Kidney Dis; 2023 Feb; 81(2):145-155.e1. PubMed ID: 35843439
[TBL] [Abstract][Full Text] [Related]
7. An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.
Liebow A; Li X; Racie T; Hettinger J; Bettencourt BR; Najafian N; Haslett P; Fitzgerald K; Holmes RP; Erbe D; Querbes W; Knight J
J Am Soc Nephrol; 2017 Feb; 28(2):494-503. PubMed ID: 27432743
[TBL] [Abstract][Full Text] [Related]
8. Progress with RNA Interference for the Treatment of Primary Hyperoxaluria.
Sawyer K; Leahy S; Wood KD
BioDrugs; 2022 Jul; 36(4):437-441. PubMed ID: 35731461
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase.
Li X; Knight J; Fargue S; Buchalski B; Guan Z; Inscho EW; Liebow A; Fitzgerald K; Querbes W; Todd Lowther W; Holmes RP
Biochim Biophys Acta; 2016 Feb; 1862(2):233-9. PubMed ID: 26655602
[TBL] [Abstract][Full Text] [Related]
10. Improving Treatment Options for Primary Hyperoxaluria.
Hoppe B; Martin-Higueras C
Drugs; 2022 Jul; 82(10):1077-1094. PubMed ID: 35779234
[TBL] [Abstract][Full Text] [Related]
11. Reduction in urinary oxalate excretion in mouse models of Primary Hyperoxaluria by RNA interference inhibition of liver lactate dehydrogenase activity.
Wood KD; Holmes RP; Erbe D; Liebow A; Fargue S; Knight J
Biochim Biophys Acta Mol Basis Dis; 2019 Sep; 1865(9):2203-2209. PubMed ID: 31055082
[TBL] [Abstract][Full Text] [Related]
12. The effects of the inactivation of Hydroxyproline dehydrogenase on urinary oxalate and glycolate excretion in mouse models of primary hyperoxaluria.
Buchalski B; Wood KD; Challa A; Fargue S; Holmes RP; Lowther WT; Knight J
Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165633. PubMed ID: 31821850
[TBL] [Abstract][Full Text] [Related]
13. Primary hyperoxaluria type 1: novel therapies at a glance.
Bacchetta J; Lieske JC
Clin Kidney J; 2022 May; 15(Suppl 1):i17-i22. PubMed ID: 35592618
[TBL] [Abstract][Full Text] [Related]
14. Stiripentol and Lumasiran as a Rescue Therapy for Oxalate Nephropathy Recurrence After Kidney Transplantation in an Adult Patient With Primary Hyperoxaluria Type 1.
Lombardi Y; Isnard P; Chavarot N; Chauvet S; Martinez F; Thervet É; Anglicheau D; Karras A
Am J Kidney Dis; 2023 Jul; 82(1):113-116. PubMed ID: 36693470
[TBL] [Abstract][Full Text] [Related]
15. Is withdrawal of nocturnal hyperhydration possible in children with primary hyperoxaluria treated with RNAi?
Biebuyck N; Destombes C; Prakash R; Boyer O
J Nephrol; 2023 Jun; 36(5):1473-1476. PubMed ID: 37209362
[TBL] [Abstract][Full Text] [Related]
16. Nedosiran: First Approval.
Syed YY
Drugs; 2023 Dec; 83(18):1729-1733. PubMed ID: 38060091
[TBL] [Abstract][Full Text] [Related]
17. Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria.
Hoppe B; Koch A; Cochat P; Garrelfs SF; Baum MA; Groothoff JW; Lipkin G; Coenen M; Schalk G; Amrite A; McDougall D; Barrios K; Langman CB
Kidney Int; 2022 Mar; 101(3):626-634. PubMed ID: 34481803
[TBL] [Abstract][Full Text] [Related]
18. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2.
Baum MA; Langman C; Cochat P; Lieske JC; Moochhala SH; Hamamoto S; Satoh H; Mourani C; Ariceta G; Torres A; Wolley M; Belostotsky V; Forbes TA; Groothoff J; Hayes W; Tönshoff B; Takayama T; Rosskamp R; Russell K; Zhou J; Amrite A; Hoppe B;
Kidney Int; 2023 Jan; 103(1):207-217. PubMed ID: 36007597
[TBL] [Abstract][Full Text] [Related]
19. Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children.
Sas DJ; Magen D; Hayes W; Shasha-Lavsky H; Michael M; Schulte I; Sellier-Leclerc AL; Lu J; Seddighzadeh A; Habtemariam B; McGregor TL; Fujita KP; Frishberg Y;
Genet Med; 2022 Mar; 24(3):654-662. PubMed ID: 34906487
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Sustained Efficacy of Lumasiran at 18 Months in Primary Hyperoxaluria Type 1.
Chiodini B; Tram N; Adams B; Hennaut E; Lolin K; Ismaili K
Front Pediatr; 2021; 9():791616. PubMed ID: 35071135
[No Abstract] [Full Text] [Related]
[Next] [New Search]
